NMN
Aliases: Nikotinamid mononukleotid · β-NMN
Last verified: 2026-09-23
The short version
An NAD+ precursor — one of the most popular "longevity" molecules. In mice it rejuvenates metabolism; in humans it reliably raises NAD+, but clinical anti-aging effects remain unproven. FDA (2022): cannot be a dietary supplement due to drug investigation. Status: research chemical. US: not permitted as supplement (FDA); EU: novel food not approved; Japan: legal.
Identity & type
- Molecular type
- mali molekul
- Origin
- An NAD+ precursor — one of the most popular "longevity" molecules.
Mechanism of action
Converts to NAD+ (via NMNAT) → supports sirtuins, PARPs and mitochondria.
Dosing & routes
Official / clinical context
No approved official document exists for NMN. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
250–1000 mg/day orally. Most commonly reported: steadier daytime energy, faster recovery and a "clearer head" over 2–4 weeks; some report better workouts. Evidence for serious anti-aging outcomes in humans is still lacking.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Most commonly reported: steadier daytime energy, faster recovery and a "clearer head" over 2–4 weeks; some report better workouts. Evidence for serious anti-aging outcomes in humans is still lacking.
Protocol — official vs community
Official / label
No approved therapeutic indication (regulated as a supplement in the US). Trials used 250–1,200 mg oral daily.
- 01Flat daily dosing
Duration: Trial-defined; the longest human data is ~1 year.
Raises NAD+ precursors; human trials show metabolic signals but no established clinical outcome benefit.
Community (anecdotal)
500 mg–1 g oral every morning, often sublingual for absorption claims.
- Cycle:
- Continuous.
- Break:
- None — daily supplementation pattern.
The morning-timing convention is about alleged circadian NAD+ rhythm, not evidence.
Human evidence
Multiple RCTs (Japan/US/China): NAD+ elevation, modest metabolic/physical effects; regulatory saga over supplement status.
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Very mild profile in trials (up to 1250 mg/day); long-term data limited.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.